 UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2022 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX , a clinical-stage immuno-oncology company focused on developing its proprietary GammabodyTM platform of bispecific gamma delta T cell engagers, today announced the Company will present data demonstrating on-mechanism pharmacodynamics for LAVA-051 in the clinic during the Society for Immunotherapy of Cancers 37th Annual Meeting, taking place in Boston, Massachusetts and virtually from November 8-12, 2022. 